SCHEMBL3325087

SCHEMBL3325087

CC(C)(C)OC(=O)N1CCCC(C(C)(C)O)C1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.53
ALDH1A1 P00352 1/20 0.53
MAPT P10636 1/20 0.53
KMT2A Q03164 1/20 0.53
HPGD P15428 1/20 0.51
EPHX1 P07099 1/20 0.46
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PREP P48147 2/20 0.43
USP30 Q70CQ3 1/20 0.43
RECQL P46063 1/20 0.42
NR1H2 P55055 1/20 0.42
PDE4B Q07343 1/20 0.42
ACKR3 P25106 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
GLS O94925 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3325082 1.00 MEN1 (0.53) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL4721444 0.93 MEN1 (0.48) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL572625 0.90 HPGD (0.50) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL23063289 0.90 HPGD (0.50) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL31140974 0.90 HPGD (0.50) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL15469641 0.89 MEN1 (0.55) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL15469635 0.89 MEN1 (0.55) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL12597751 0.89 MEN1 (0.55) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL31556728 0.86 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL25916363 0.86 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4027995-B1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS SATURN INC (US) 2026-05-27 EP disclosed
US-12466841-B2 Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists Nimbus Saturn, Inc. (US) 2025-11-11 US disclosed
CN-119874700-A HPK1 antagonists and uses thereof 林伯士萨顿公司 2025-04-25 CN disclosed
US-12215105-B2 HPK1 antagonists and uses thereof Nimbus Saturn, Inc. (US) 2025-02-04 US disclosed
CN-114945366-B HPK1 antagonists and uses thereof 林伯士萨顿公司 2025-01-07 CN disclosed
WO-2024206628-A1 MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN NALO THERAPEUTICS (US) 2024-10-03 WO disclosed
US-12071442-B2 Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists Nimbus Saturn, Inc. (US) 2024-08-27 US disclosed
WO-2024149728-A1 SUBSTITUTED (HETERO)ANILINES AND THEIR USE ASTRAZENECA AB (SE) 2024-07-18 WO disclosed
US-20240190895-A1 SUBSTITUTED PYRROLO[3,4-c]PYRIDINES AS HPK1 ANTAGONISTS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2024-06-13 US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 US disclosed
WO-2021050964-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2021-03-18 WO disclosed
US-20210078997-A1 SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-03-18 US disclosed
US-20210078998-A1 SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-03-18 US disclosed
US-20210078998-A1 SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2021-03-18 US disclosed
US-20100120858-A1 Piperidine Derivatives PFIZER INC. 2010-05-13 US disclosed
EP-2066630-A1 PIPERIDINE DERIVATIVES Pfizer Products Incorporated (US) 2009-06-10 EP disclosed
US-20090054440-A1 Quinoline derivatives as neurokinin receptor antagonists CARLING WILLIAM ROBERT 2009-02-26 US disclosed
WO-2008023258-A1 PIPERIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-02-28 WO disclosed
EP-1888530-A2 QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2008-02-20 EP disclosed
WO-2006120478-A2 QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2006-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210078998-A1 SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS HIPK1, PDXK, IP6K1 MEN1 3531/4885ALDH1A1 4044/4885MAPT 3245/4885
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 MEN1 2440/4885ALDH1A1 4740/4885MAPT 3895/4885
US-20090054440-A1 Quinoline derivatives as neurokinin receptor antagonists TACR2, TACR3, NPY2R MEN1 1001/4885ALDH1A1 2836/4885MAPT 4195/4885
US-20100120858-A1 Piperidine Derivatives P2RX5, P2RX7, P2RX1 MEN1 2104/4885ALDH1A1 128/4885MAPT 3998/4885
US-12466841-B2 Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists PDXK, HIPK1, HIPK3 MEN1 3406/4885ALDH1A1 4707/4885MAPT 3393/4885
US-12071442-B2 Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists PDXK, HIPK1, PGK1 MEN1 3250/4885ALDH1A1 4487/4885MAPT 3822/4885
US-20240190895-A1 SUBSTITUTED PYRROLO[3,4-c]PYRIDINES AS HPK1 ANTAGONISTS PDXK, HIPK1, HIPK3 MEN1 3406/4885ALDH1A1 4707/4885MAPT 3393/4885
US-20210078997-A1 SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS HIPK1, PDXK, IP6K1 MEN1 3620/4885ALDH1A1 3749/4885MAPT 3099/4885
US-12215105-B2 HPK1 antagonists and uses thereof PDXK, HIPK1, PCK1 MEN1 2440/4885ALDH1A1 4740/4885MAPT 3895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.